Infusion of bispecific monoclonal antibody complexes into monkeys provides immunologic protection against later challenge with a model pathogen

Clinical Immunology

Volumn 92, Issue 2, 1999, Pages 170-180

  Craig, Maria L ^a   Reinagel, Michele L ^a   Martin, Edward N ^a   Schlimgen, Ryan ^a   Nardin, Alessandra ^a   Taylor, Ronald P ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Bispecific antibodies; Complement receptor; Erythrocyte; Nonhuman primate

Indexed keywords

COMPLEMENT COMPONENT C1; COMPLEMENT RECEPTOR; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANTIGEN BINDING; ARTICLE; COMPLEMENT ACTIVATION; ERYTHROCYTE; HOST RESISTANCE; IMMUNOREGULATION; MONKEY; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST;

EID: 0032780458     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1006/clim.1999.4739     Document Type: Article

References (36)

1. Frank M. M. Complement in the pathophysiology of human disease. N. Engl. J. Med. 316:1987;1525-1530.
2. Kirschfink M. Controlling the complement system in inflammation. Immunopharmacology. 38:1997;51-62.
3. Makrides S. C. Therapeutic inhibition of the complement system. Pharm. Rev. 50:1998;59-87.
4. Gadjeva M., Dodds A. W., Taniguchi-Sidle A., Willis A. C., Isenman D. E., Law S. K. The covalent binding reaction of complement component C3. J. Immunol. 161:1998;985-990.
5. Ochs H. D., Nonoyama S., Zhu Q., Farrington M., Wedgwood R. J. Regulation of antibody responses: The role of complement and adhesion molecules. Clin. Immunol. Immunopathol. 67:1993;S33-S40.
6. Tolnay M., Tsokos G. C. Complement receptor 2 in the regulation of the immune response. Clin. Immunol. Immunopathol. 88:1998;123-132.
7. Nelson R. A. The immune-adherence phenomenon. An immunologically specific reaction between microorganisms and erythrocytes leading to enhanced phagocytosis. Science. 118:1953;733-737.
8. Fearon D. T. Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyte. J. Exp. Med. 152:1980;20-30.
9. Cornacoff J. B., Hebert L. A., Smead W. L., Van Aman M. E., Birmingham D. J., Waxman F. J. Primate erythrocyte-immune complex-clearing mechanism. J. Clin. Invest. 71:1983;236-247.
10. Hebert L. A. The erythrocyte-immune complex-glomerulonephritis connection in man. Kidney Int. 31:1987.
11. Schifferli J. A., Taylor R. P. Physiological and pathological aspects of circulating immune complexes. Kidney Int. 35:1989;993-1003.
12. Taylor R. P., Sutherland W. M., Reist C. J., Webb D. J., Wright E. L., Labuguen R. H. Use of heteropolymeric monoclonal antibodies to attach antigens to the C3b receptor of human erythrocytes: A potential therapeutic treatment. Proc. Natl. Acad. Sci. USA. 88:1991;3305-3309.
13. Taylor R. P., Ferguson P. J. Primate erythrocyte (E) complement receptor (CR1) as an anchor site for bispecific-based therapies to clear pathogens or autoantibodies safely from the circulation. J. Hematother. 4:1995;357-362.
14. Taylor R. P., Sutherland W. M., Martin E. N., Ferguson P. J., Reinagel M. L., Gilbert E., Lopez K., Incardona N. L., Ochs H. D. Bispecific monoclonal antibody complexes bound to primate erythrocyte complement receptor 1 facilitate virus clearance in a monkey model. J. Immunol. 158:1997;842-850.
15. Taylor R. P., Martin E. N., Reinagel M. L., Nardin A., Craig M., Choice Q., Schlimgen R., Greenbaum S., Incardona N. L., Ochs H. D. Bispecific monoclonal antibody complexes facilitate erythrocyte binding and liver clearance of a prototype particulate pathogen in a monkey model. J. Immunol. 159:1997;4035-4044.
16. Kuhn S. E., Nardin A., Klebba P. E., Taylor R. P. Escherichia coli bound to the primate erythrocyte complement receptor via bispecific monoclonal antibodies are transferred to and phagocytosed by human monocytes in an in vitro model. J. Immunol. 160:1998;5088-5097.
17. Malaise M. G., Franchimont P., Mahieu P. R. The ability of normal human monocytes to phagocytose IgG-coated red blood cells is related to the number of accessable galactosyl and mannosyl residues in the Fc domain of the anti-red blood cell IgG antibody molecules. J. Immunol. Methods. 119:1989;231-239.
18. Frank M. M. The role of macrophages in blood stream clearance. Zembala M., Asherson G. L. Human Monocytes. 1989;337-344 Academic Press, London.
19. Masouredis, S. P., Branks, M. J., Pierce, S. W., and Victoria, E. J., Nonhemolytic red cell autoantibodies consist of multiple immunoglobulin G populations directed against complex membrane epitopes. J. Lab. Clin. Med.113, 569-576, 1989.
20. Indik Z. K., Park J. G., Hunter S., Schreiber A. D. The molecular dissection of FcγRIII receptor mediated phagocytosis. Blood. 86:1995;4389-4399.
21. Reinagel M. L., Gezen M., Ferguson P. J., Kuhn S., Martin E. N., Taylor R. P. The primate erythrocyte complement receptor (CR1) as a privileged site: Binding of immunoglobulin G to erythrocyte CR1 does not target erythrocytes for phagocytosis. Blood. 89:1997;1068-1077.
22. Taylor R. P., Ferguson P. J., Martin E. N., Cooke J., Greene K. L., Grinspun K., Guttman M., Kuhn S. Immune complexes bound to the primate erythrocyte complement receptor (CR1) via anti-CR1 mabs are cleared simultaneously with loss of CR1 in a concerted reaction in a rhesus monkey model. Clin. Immunol. Immunopathol. 82:1997;49-59.
23. Reist C. J., Liang H. Y., Denny D., Martin E. N., Scheld W. M., Taylor R. P. Cross-linked bispecific monoclonal antibody heteropolymers facilitate the clearance of human IgM from the circulation of squirrel monkeys. Eur. J. Immunol. 24:1994;2018-2025.
24. Ferguson P. J., Martin E. N., Greene K. L., Kuhn S., Cafiso D. S., Addona G., Taylor R. P. Antigen-based heteropolymers facilitate, via primate erythrocyte complement receptor type 1, rapid erythrocyte binding of an autoantibody and its clearance from the circulation in rhesus monkeys. J. Immunol. 155:1995;339-347.
25. Kimberly R. P., Edberg J. C., Merriam L. T., Clarkson S. B., Unkeless J. C., Taylor R. P. In vivo handling of soluble complement fixing Ab/dsDNA immune complexes in chimpanzees. J. Clin. Invest. 84:1989;962-970.
26. Ross G. D., Yount W. J., Walport M. J., Winfield J. B., Parker C. J., Fuller C. R., Taylor R. P., Myones B. L., Lachmann P. J. Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation. J. Immunol. 135:1985;2005-2014.
27. Kimberly R. P., Salmon J. E., Edberg J. C. Receptors for immunoglobulin G: Molecular diversity and implications for disease. Arthritis Rheum. 38:1995;306-314.
28. Segal D. M., Bast B. Production of bispecific antibodies. Coligan J. E., Kruisbeek A. M., Shevach E. M., Strober W. Current Protocols in Immunology. 1995;2.13.1-2.13.15 Wiley, New York.
29. Huser H.-J. Atlas of Comparative Primate Hematology. 1970;Academic Press, New York.
30. Kurlander R. J., Ellison D. M., Hall J. The blockade of Fc receptor-mediated clearance of immune complexes in vivo by a monoclonal antibody (2.4G2) directed against Fc receptors on murine leukocytes. J. Immunol. 133:1984;855-862.
31. Cohen J. H. M., Lutz H. U., Pennaforte J. L., Bouchard A., Kazatchkine M. D. Peripheral catabolism of CR1 (the C3b receptor, CD35) on erythrocytes from healthy individuals and patients with systemic lupus erythematosus (SLE). Clin. Exp. Immunol. 87:1992;422-428.
32. Kreger B. E., Craven D. E., Carling P. C., McCabe W. R. Gram-negative bacteremia: Reassessment of etiology, epidemiology and ecology in 612 patients. Am. J. Med. 68:1980;332-343.
33. Cross A. S., Opal S. M., Sadoff J. C., Gemski P. Choice of bacteria in animal models of sepsis. Infect. Immun. 61:1993;2741-2747.
34. Ho D. D. Perspectives series: Host/pathogen interactions (dynamics of HIV-1 replication in vivo). J. Clin. Invest. 99:1997;2565-2567.
35. Galili U. Interaction of the natural anti-Gal antibody with a-galactosyl epitopes: A major obstacle for xenotransplantation in humans. Immunol. Today. 14:1993;480-482.
36. Borrebaeck C. A. K., Malmborg A., Ohlin M. Does endogenous glycosylation prevent the use of mouse monoclonal antibodies as cancer therapeutics? Immunol. Today. 14:1993;477-479.